ASSESSMENT OF ATORVASTATIN EFFECTIVENESS ON SERUM PSA LEVEL IN HYPERCHOLESTEROLEMIC MALES

Q: How can I download an article?

To download an article from SID, first log in to the site, search for the article title, and click on the 'Download Article' option.

Q: How can I download an ISI article?

To download an ISI article on SID, enter the keyword or article title in the search bar, view the relevant results, click on the desired article, and select the 'Download Article' option.

Q: How can I access the SID database?

To access the SID database, visit SID.ir, create an account, and log in to access scientific resources.

Q: Is downloading articles from SID free?

Some articles on SID are available for free, while others require payment. Details are specified on the article's page.

KHOSROPANAH IRADJ; FALAHATKAR SIAVASH; FARHAT BABAK; HEIDARI BATENI ZHOOBIN; ENSHAEI AHMAD; ALLAHKHAH ALI AKBAR; KHOSROPANAH DARYA

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Journal Paper

Paper Information

Journal: ACTA MEDICA IRANICA Year:2011 | Volume:49 | Issue:12 Page(s): 789-794

Download Full-Text

View:

345

Download:

Cites:

Information Journal Paper

Title

ASSESSMENT OF ATORVASTATIN EFFECTIVENESS ON SERUM PSA LEVEL IN HYPERCHOLESTEROLEMIC MALES

Author(s)

Keywords

ATORVASTATIN

SERUM PSA LEVEL

HYPERCHOLESTEROLEMIC MALE

PROSTATE CANCER

Abstract

The previous large retrospective studies demonstrated that treatment with Statins reduces both the incidence of PROSTATE CANCER by 50% and serum Prostate Specific Antigen (PSA) level up to 40%. However the main problem in those studies was the absence of control groups of men with hypercholesterolemia without Statin treatment. We performed a small prospective controlled clinical trial to assess the influence of the treatment with ATORVASTATIN on serum PSA in men with hypercholesterolemia referred to our educational and treatment center from October 2007 to March 2008. In this study, among the newly diagnosed males with hypercholesterolemia (LDL>130 mg/dl), 40 patients with LDL more than 190 mg/dl were selected as a case group and were treated with ATORVASTATIN (20 mg/day). Among the same population and in the same period, another 40 patients with LDL between 130 and 190 mg/dl were selected as first control group and were treated only with low fat diet. Another 40 patients with normal serum cholesterol and without any treatment were selected as second control group. The lipid profile and SERUM PSA LEVEL of patients of all groups were tested at the first and third months after the therapy. After completion of data, the mean serum lipids and PSA level were measured in both visits and compared with each other by paired t-test. Also the mean PSA change in two visits between three groups was compared by ANOVA and Tukey HSD test. There was not any significant difference in mean baseline PSA between hypercholesterolemic and normocholesterolemic patients (P=0.547). In case group, mean PSA and LDL was reduced by 14.1% (P=0.0001) and 30% (P=0.0001) respectively by second visit. In first control group, mean PSA was not changed significantly (P=0.337), whereas mean LDL in this group was reduced by 9.6% (P=0.0001). Similarly in the second control group mean PSA was not changed significantly (P=0.309) by second visit. In addition, mean change of PSA in case group was compared with first and second control groups that was significantly different (P=0.0001) whereas mean change of PSA between two control groups was not significantly different (P=0.615). The results of this study showed that: 1) Short term treatment with ATORVASTATIN can reduce SERUM PSA LEVEL, and 2) This reduction is more likely to be due to direct effect and is not related to lowering serum cholesterol levels. Thus, if results of this study are confirmed by large prospective randomized clinical trials with longer follow up period, it will be possible that ATORVASTATIN could be used in long term as a safe chemoprophylactic agent against PROSTATE CANCER in high risk patients.

Cites

No record.

References

No record.

Cite

APA: Copy

KHOSROPANAH, IRADJ, FALAHATKAR, SIAVASH, FARHAT, BABAK, HEIDARI BATENI, ZHOOBIN, ENSHAEI, AHMAD, ALLAHKHAH, ALI AKBAR, & KHOSROPANAH, DARYA. (2011). ASSESSMENT OF ATORVASTATIN EFFECTIVENESS ON SERUM PSA LEVEL IN HYPERCHOLESTEROLEMIC MALES. ACTA MEDICA IRANICA, 49(12), 789-794. SID. https://sid.ir/paper/278568/en

Vancouver: Copy

KHOSROPANAH IRADJ, FALAHATKAR SIAVASH, FARHAT BABAK, HEIDARI BATENI ZHOOBIN, ENSHAEI AHMAD, ALLAHKHAH ALI AKBAR, KHOSROPANAH DARYA. ASSESSMENT OF ATORVASTATIN EFFECTIVENESS ON SERUM PSA LEVEL IN HYPERCHOLESTEROLEMIC MALES. ACTA MEDICA IRANICA[Internet]. 2011;49(12):789-794. Available from: https://sid.ir/paper/278568/en

IEEE: Copy

IRADJ KHOSROPANAH, SIAVASH FALAHATKAR, BABAK FARHAT, ZHOOBIN HEIDARI BATENI, AHMAD ENSHAEI, ALI AKBAR ALLAHKHAH, and DARYA KHOSROPANAH, “ASSESSMENT OF ATORVASTATIN EFFECTIVENESS ON SERUM PSA LEVEL IN HYPERCHOLESTEROLEMIC MALES,” ACTA MEDICA IRANICA, vol. 49, no. 12, pp. 789–794, 2011, [Online]. Available: https://sid.ir/paper/278568/en

Related Journal Papers

No record.

Related Seminar Papers

No record.

Related Plans

No record.

Recommended Workshops